1.Sales and profit
See section β- Spyre Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
- Spyre Therapeutics, Inc. lost $155M in fiscal 2025.
Spyre Therapeutics, Inc.
SYRE Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Spyre Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
- Today
- 2.9%
- Previous close
- $90.33
- Market cap
- β
- P/E
- β
- 52-week range
-
$22.18 $108.92
Last close Β· Oct 26, 2026
$92.91
+$69.54 (+297.56%) past year
KIRAβs summary AI analyst
Hi! I read Spyre Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
1 to watch
2.Cash and shareholders
See section β- In the last 12 months, insiders sold $443M of shares on the open market and bought none.
Spyre Therapeutics, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$155M
No. It lost money last year.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
β
Oct 26 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
KIRA summarises the numbers
-
Spyre Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
Revenue
FY16
Revenue $4.6M
FY17
Revenue $5.2M
FY18
Revenue $3.9M
FY19
Revenue $0.0M
FY20
Revenue $0.0M
FY21
Revenue $18.7M
FY22
Revenue $2.3M
FY23
Revenue $0.9M
FY24
Revenue $0.0M
FY25
Revenue $0.0M
Revenue
Q3 '23
Revenue $0.0M
Q4 '23
Revenue $0.0M
Q1 '24
Revenue $0.0M
Q2 '24
Revenue $0.0M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue β
Q2 '25
Revenue β
Q3 '25
Revenue β
Q4 '25
Revenue β
Q1 '26
Revenue β
Q2 '26
Revenue β
Margins, % of revenue
FY16
Gross β
Operating β473.3%
Net β468.8%
FCF β411.7%
FY17
Gross β
Operating β531.7%
Net β523.3%
FCF β484.8%
FY18
Gross β
Operating β1,169.3%
Net β1,140.6%
FCF β838.9%
FY19
Gross β
Operating β
Net β
FCF β
FY20
Gross β
Operating β
Net β
FCF β
FY21
Gross β
Operating β350.3%
Net β351.1%
FCF β289.7%
FY22
Gross β
Operating β3,640.2%
Net β3,598.8%
FCF β3,442.8%
FY23
Gross β
Operating β27,348.0%
Net β38,238.1%
FCF β11,276.5%
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Spyre Therapeutics, Inc. lost $155M in fiscal 2025.
Net income
FY16
Net income β$21.7M
FY17
Net income β$27.2M
FY18
Net income β$44.3M
FY19
Net income β$78.3M
FY20
Net income β$80.9M
FY21
Net income β$65.8M
FY22
Net income β$83.8M
FY23
Net income β$339M
FY24
Net income β$208M
FY25
Net income β$155M
Net income
Q3 '23
Net income β$40.1M
Q4 '23
Net income β$63.2M
Q1 '24
Net income β$43.9M
Q2 '24
Net income β$38.8M
Q3 '24
Net income β$69.0M
Q4 '24
Net income β$56.3M
Q1 '25
Net income β$44.8M
Q2 '25
Net income β$36.7M
Q3 '25
Net income β$11.2M
Q4 '25
Net income β$62.5M
Q1 '26
Net income β$69.0M
Q2 '26
Net income β$36.2M
Diluted EPS
FY16
Diluted EPS β$2.22
FY17
Diluted EPS β$1.80
FY18
Diluted EPS β$2.13
FY19
Diluted EPS β$2.45
FY20
Diluted EPS β$1.52
FY21
Diluted EPS β$25.02
FY22
Diluted EPS β$24.86
FY23
Diluted EPS $13.76
FY24
Diluted EPS β
FY25
Diluted EPS β
Diluted EPS
Q3 '23
Diluted EPS $0.86
Q4 '23
Diluted EPS β$22.35
Q1 '24
Diluted EPS $0.72
Q2 '24
Diluted EPS $0.59
Q3 '24
Diluted EPS $1.06
Q4 '24
Diluted EPS β
Q1 '25
Diluted EPS β
Q2 '25
Diluted EPS β
Q3 '25
Diluted EPS β
Q4 '25
Diluted EPS β
Q1 '26
Diluted EPS β$0.74
Q2 '26
Diluted EPS β
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
Free cash flow
FY16
Free cash flow β$19.1M
FY17
Free cash flow β$25.2M
FY18
Free cash flow β$32.6M
FY19
Free cash flow β$67.2M
FY20
Free cash flow β$80.1M
FY21
Free cash flow β$54.3M
FY22
Free cash flow β$80.2M
FY23
Free cash flow β$99.9M
FY24
Free cash flow β$157M
FY25
Free cash flow β
Free cash flow
Q3 '23
Free cash flow β
Q4 '23
Free cash flow β$31.0M
Q1 '24
Free cash flow β
Q2 '24
Free cash flow β
Q3 '24
Free cash flow β
Q4 '24
Free cash flow β
Q1 '25
Free cash flow β
Q2 '25
Free cash flow β
Q3 '25
Free cash flow β
Q4 '25
Free cash flow β
Q1 '26
Free cash flow β
Q2 '26
Free cash flow β
Cash from operations vs capital spending
FY16
Cash from operations β$18.8M
Capital spending $0.2M
FY17
Cash from operations β$24.6M
Capital spending $0.6M
FY18
Cash from operations β$32.2M
Capital spending $0.4M
FY19
Cash from operations β$65.7M
Capital spending $1.5M
FY20
Cash from operations β$75.8M
Capital spending $4.3M
FY21
Cash from operations β$53.7M
Capital spending $0.6M
FY22
Cash from operations β$80.1M
Capital spending $0.0M
FY23
Cash from operations β$99.9M
Capital spending $0.0M
FY24
Cash from operations β$157M
Capital spending $0.0M
FY25
Cash from operations β$169M
Capital spending β
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations β$34.6M
Capital spending β
Q4 '23
Cash from operations β$31.0M
Capital spending $0.0M
Q1 '24
Cash from operations β$28.5M
Capital spending β
Q2 '24
Cash from operations β$62.2M
Capital spending β
Q3 '24
Cash from operations β$29.4M
Capital spending β
Q4 '24
Cash from operations β$37.2M
Capital spending β
Q1 '25
Cash from operations β$41.0M
Capital spending β
Q2 '25
Cash from operations β$46.6M
Capital spending β
Q3 '25
Cash from operations β$37.1M
Capital spending β
Q4 '25
Cash from operations β$44.6M
Capital spending β
Q1 '26
Cash from operations β$57.4M
Capital spending β
Q2 '26
Cash from operations β$69.9M
Capital spending β
Cash from operations
Capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends, buybacks and share count
Dividends and buybacks
FY16
Dividends β
Buybacks β
FY17
Dividends β
Buybacks β
FY18
Dividends β
Buybacks β
FY19
Dividends β
Buybacks β
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY16
Diluted shares 0.01B
FY17
Diluted shares 0.02B
FY18
Diluted shares 0.02B
FY19
Diluted shares 0.03B
FY20
Diluted shares 0.05B
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.01B
FY24
Diluted shares β
FY25
Diluted shares β
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
In the last 12 months, insiders sold $443M of shares on the open market and bought none.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$443M
7 insiders
Of sales under plans
9%
$42.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 7,500 | $91.83 | $0.7M | Form 4 |
| Oct 1, 2026 | Heidy King-JonesSee Remarks | Sold plan | 28,933 | $91.03 | $2.6M | Form 4 |
| Oct 1, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $92.01 | $1.4M | Form 4 |
| Sep 30, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 17,500 | $89.89 | $1.6M | Form 4 |
| Sep 2, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 18,232 | $89.35 | $1.6M | Form 4 |
| Sep 2, 2026 | Heidy King-JonesSee Remarks | Sold plan | 400 | $90.00 | $0.0M | Form 4 |
| Sep 1, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 7,500 | $87.31 | $0.7M | Form 4 |
| Sep 1, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $87.29 | $1.3M | Form 4 |
| Sep 1, 2026 | Heidy King-JonesSee Remarks | Sold plan | 27,999 | $87.31 | $2.4M | Form 4 |
| Aug 7, 2026 | Jeffrey W. AlbersDirector | Sold plan | 23,000 | $104.53 | $2.4M | Form 4 |
| Aug 3, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 7,500 | $95.57 | $0.7M | Form 4 |
| Aug 3, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $95.51 | $1.4M | Form 4 |
| Jul 1, 2026 | Sheldon SloanChief Medical Officer | Sold plan | 8,334 | $87.70 | $0.7M | Form 4 |
| Jul 1, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 7,500 | $87.74 | $0.7M | Form 4 |
| Jul 1, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $87.69 | $1.3M | Form 4 |
| Jun 25, 2026 | Scott L BurrowsChief Financial Officer | Sold | 15,000 | $87.13 | $1.3M | Form 4 |
| Jun 23, 2026 | Fairmount Funds Management LLCDirector | Sold | 4,684,781 | $85.31 | $400M | Form 4 |
| Jun 22, 2026 | Michael Thomas HendersonDirector | Sold plan | 20,000 | $100.00 | $2.0M | Form 4 |
| Jun 3, 2026 | Sheldon SloanChief Medical Officer | Sold plan | 8,333 | $75.00 | $0.6M | Form 4 |
| Jun 1, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $70.43 | $1.1M | Form 4 |
| Jun 1, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 7,500 | $71.06 | $0.5M | Form 4 |
| May 8, 2026 | Michael Thomas HendersonDirector | Sold plan | 80,000 | $74.40 | $6.0M | Form 4 |
| May 1, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 12,500 | $71.37 | $0.9M | Form 4 |
| May 1, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $71.37 | $1.1M | Form 4 |
| May 1, 2026 | Sheldon SloanChief Medical Officer | Sold plan | 78,333 | $71.50 | $5.6M | Form 4 |
| Apr 1, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 7,500 | $49.34 | $0.4M | Form 4 |
| Apr 1, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $49.33 | $0.7M | Form 4 |
| Apr 1, 2026 | Sheldon SloanChief Medical Officer | Sold plan | 7,958 | $50.00 | $0.4M | Form 4 |
| Mar 3, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 2,500 | $40.65 | $0.1M | Form 4 |
| Mar 2, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $42.19 | $0.6M | Form 4 |
| Feb 2, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $32.80 | $0.5M | Form 4 |
| Jan 2, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $30.68 | $0.5M | Form 4 |
| Dec 1, 2025 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $29.02 | $0.4M | Form 4 |
| Nov 3, 2025 | Cameron TurtleChief Executive Officer, Director | Sold plan | 45,000 | $23.33 | $1.0M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Spyre Therapeutics, Inc. can carry it.
Cash vs debt (incl. leases)
FY16
Cash $63.5M
Debt β
FY17
Cash $50.3M
Debt β
FY18
Cash $74.5M
Debt β
FY19
Cash $71.9M
Debt β
FY20
Cash $146M
Debt β
FY21
Cash $93.1M
Debt β
FY22
Cash $55.7M
Debt β
FY23
Cash $339M
Debt β
FY24
Cash $603M
Debt β
FY25
Cash $757M
Debt β
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $93.1M | $55.7M | $339M | $603M | $757M |
| Current ratio | 4.9x | 4.2x | 10.7x | 11.3x | 13.3x |
| Quick ratio | 4.9x | 4.2x | 10.7x | 11.3x | 13.3x |
| Total assets | $110M | $71.1M | $342M | $608M | $778M |
| Total liabilities | $26.0M | $20.8M | $73.3M | $90.7M | $62.5M |
| Shareholders' equity | $83.9M | $50.3M | $184M | $518M | $715M |
| Net debt (β = net cash) | β | β | β | β | β |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
FY16
Return on capital β
Return on equity β34.5%
Return on assets β32.4%
FY17
Return on capital β
Return on equity β48.1%
Return on assets β44.2%
FY18
Return on capital β
Return on equity β75.3%
Return on assets β66.3%
FY19
Return on capital β
Return on equity β122.7%
Return on assets β97.3%
FY20
Return on capital β
Return on equity β80.9%
Return on assets β66.1%
FY21
Return on capital β
Return on equity β58.8%
Return on assets β48.5%
FY22
Return on capital β
Return on equity β124.9%
Return on assets β92.6%
FY23
Return on capital β
Return on equity β289.2%
Return on assets β164.1%
FY24
Return on capital β
Return on equity β59.3%
Return on assets β43.8%
FY25
Return on capital β
Return on equity β25.2%
Return on assets β22.4%
Return on capital
Return on equity
Return on assets
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 1 / 7 | 1 / 7 | 3 / 7 | 3 / 7 | 1 / 7 | 3 / 7 | β / 6 | β / 6 |
| Accruals ratio | β4.3% | β4.3% | β18.2% | β15.6% | β4.2% | β8.9% | β4.1% | β115.7% | β10.7% | 2.0% |
| Altman Z'' | 17.85 | 7.45 | 3.64 | β6.98 | 3.20 | β6.06 | β20.59 | β3.48 | 4.46 | 11.54 |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
Every number, year by year.
10 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $4.6M | $5.2M | $3.9M | $0.0M | $0.0M | $18.7M | $2.3M | $0.9M | $0.0M | $0.0M |
| Research and development | $18.1M | $22.8M | $36.7M | $64.6M | $59.6M | $57.1M | $58.6M | $89.5M | $163M | $172M |
| Operating income | β$21.9M | β$27.7M | β$45.5M | β$80.3M | β$81.5M | β$65.6M | β$84.8M | β$242M | β$209M | β$210M |
| Pretax income | β | β | β | β$78.3M | β$80.9M | β$65.7M | β$84.0M | β$339M | β$208M | β$155M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | β$0.1M | β$0.0M | $0.1M | β$0.0M |
| Net income | β$21.7M | β$27.2M | β$44.3M | β$78.3M | β$80.9M | β$65.8M | β$83.8M | β$339M | β$208M | β$155M |
| Net income to common | β$21.7M | β$27.2M | β | β | β | β | β | β | β | β |
| Diluted EPS | β$2.22 | β$1.80 | β$2.13 | β$2.45 | β$1.52 | β$25.02 | β$24.86 | $13.76 | β | β |
| Diluted shares | 0.01B | 0.02B | 0.02B | 0.03B | 0.05B | 0.00B | 0.00B | 0.01B | β | β |
| Cash flow | ||||||||||
| Cash from operations | β$18.8M | β$24.6M | β$32.2M | β$65.7M | β$75.8M | β$53.7M | β$80.1M | β$99.9M | β$157M | β$169M |
| Capital expenditure | $0.2M | $0.6M | $0.4M | $1.5M | $4.3M | $0.6M | $0.0M | $0.0M | $0.0M | β |
| Free cash flow | β$19.1M | β$25.2M | β$32.6M | β$67.2M | β$80.1M | β$54.3M | β$80.2M | β$99.9M | β$157M | β |
| Depreciation and amortization | $0.1M | $0.2M | $0.3M | $0.4M | $1.0M | $1.6M | $1.6M | $0.7M | $0.0M | $0.0M |
| Stock-based compensation | $1.2M | $2.5M | $4.3M | $4.9M | $6.3M | $8.0M | $7.1M | $25.7M | $44.8M | $37.6M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $63.5M | $50.3M | $74.5M | $71.9M | $146M | $93.1M | $55.7M | $339M | $603M | $757M |
| Finance lease liabilities | β | β | β | $0.1M | $0.1M | $0.4M | $0.0M | β | β | β |
| Current assets | $66.4M | $55.0M | $76.7M | $74.5M | $150M | $98.9M | $62.3M | $342M | $608M | $778M |
| Current liabilities | $4.0M | $5.6M | $10.2M | $18.4M | $16.4M | $20.1M | $14.7M | $32.0M | $54.1M | $58.7M |
| Property and equipment, net | $0.6M | $0.9M | $1.0M | $2.4M | $5.6M | $4.5M | $3.2M | $0.0M | β | β |
| Total assets | $67.1M | $56.1M | $77.7M | $83.2M | $162M | $110M | $71.1M | $342M | $608M | $778M |
| Total liabilities | $4.1M | $5.7M | $10.3M | $23.1M | $21.8M | $26.0M | $20.8M | $73.3M | $90.7M | $62.5M |
| Preferred stock | β | β | β | β | β | $0.0M | $0.0M | β | β | β |
| Shareholders' equity | $63.0M | $50.3M | $67.4M | $60.1M | $140M | $83.9M | $50.3M | $184M | $518M | $715M |
| Margins | ||||||||||
| Operating margin | β473.3% | β531.7% | β1,169.3% | β | β | β350.3% | β3,640.2% | β27,348.0% | β | β |
| EBITDA margin | β470.5% | β526.9% | β1,161.8% | β | β | β341.9% | β3,572.9% | β27,264.0% | β | β |
| Net margin | β468.8% | β523.3% | β1,140.6% | β | β | β351.1% | β3,598.8% | β38,238.1% | β | β |
| FCF margin | β411.7% | β484.8% | β838.9% | β | β | β289.7% | β3,442.8% | β11,276.5% | β | β |
| Returns | ||||||||||
| Return on capital employed | β34.7% | β54.9% | β67.4% | β123.9% | β56.1% | β73.1% | β150.1% | β78.2% | β37.6% | β29.1% |
| Return on equity | β34.5% | β48.1% | β75.3% | β122.7% | β80.9% | β58.8% | β124.9% | β289.2% | β59.3% | β25.2% |
| Return on assets | β32.4% | β44.2% | β66.3% | β97.3% | β66.1% | β48.5% | β92.6% | β164.1% | β43.8% | β22.4% |
| Return on tangible equity | β34.5% | β54.1% | β65.8% | β130.2% | β57.9% | β78.4% | β166.6% | β184.1% | β40.2% | β21.7% |
| Growth | ||||||||||
| Revenue growth | β | 12.5% | β25.3% | β100.0% | β | β | β87.6% | β62.0% | β100.0% | β |
| Share count change | β | 54.5% | 37.6% | 53.4% | 67.0% | β95.1% | 28.2% | 104.6% | β | β |
| Financial health | ||||||||||
| Current ratio | 16.8x | 9.8x | 7.5x | 4.1x | 9.1x | 4.9x | 4.2x | 10.7x | 11.3x | 13.3x |
| Quick ratio | 16.8x | 9.8x | 7.5x | 4.1x | 9.1x | 4.9x | 4.2x | 10.7x | 11.3x | 13.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 4.6% | 11.9% | 10.9% | β | β | 3.1% | 1.6% | 0.0% | β | β |
| Stock comp / revenue | 26.4% | 47.9% | 110.1% | β | β | 42.9% | 305.3% | 2,897.9% | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 1.0 | 1.0 | 3.0 | 3.0 | 1.0 | 3.0 | β | β |
| Altman Z'' | 17.9 | 7.5 | 3.6 | β7.0 | 3.2 | β6.1 | β20.6 | β3.5 | 4.5 | 11.5 |
| Accruals ratio | β4.3% | β4.3% | β18.2% | β15.6% | β4.2% | β8.9% | β4.1% | β115.7% | β10.7% | 2.0% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0001636282). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.